The Female Health Company Receives Order from UNFPA for 20 Million FC2 Female Condoms for Brazil to be Delivered Within FY2012
CHICAGO, Dec.14, 2011 /PRNewswire/ — The Female Health Company (Nasdaq: FHCO), today announced that it has received an order from UNFPA for 20 million FC2 Female Condoms for Brazil. Delivery under the contract is expected to commence in March, 2012 and conclude within fiscal year 2012.
Earlier the Company had announced that a tender had been awarded for up to 20 million units. The order just received covers the entire quantity of the tender.
O.B. Parrish, Chairman and C.E.O. of The Female Health Company, noted that the order reflects Brazil’s leadership in providing women with options to control their health and in further enhancing their national HIV/AIDS prevention program. It also reflects UNFPA’s remarkable global contribution to HIV/AIDS prevention.
“We are very encouraged by recent indications of demand growth from customers that distribute female condoms globally and believe the long-term outlook for the Company remains positive for three reasons: the feminization of HIV/AIDS, the complexity of developing easy-to-use alternative prevention methods, and the emergence of drug resistant strains of sexually transmitted infections (STI’s).”
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female CondomÃ‚® (FC2), which is available in the U.S. and in about 120 other countries globally. The Company owns certain worldwide rights to the FC2 Female CondomÃ‚®, including patents that have been issued in the U.S., the European Union, Canada, Australia, South Africa, Japan, The People’s Republic of China, Spain, Mexico, Greece, Turkey and the African Regional Intellectual Property Organization (ARIPO), which includes Botswana, The Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Somalia, Sudan, Swaziland, Uganda, United Republic of Tanzania, Zambia and Zimbabwe. FC2 patent applications are pending in various countries. The FC2 Female CondomÃ‚® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.
“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995:
The statements in this release which are not historical fact are “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release relate to the timing of deliveries under the order for Brazil. These statements are based upon the Company’s current plans and strategies, and reflect the Company’s current assessment of the risks and uncertainties related to its business, and are made as of the date of this release. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events, developments or circumstances. Such forward-looking statements are inherently subject to known and unknown risks and uncertainties. The Company’s actual results and future developments could differ materially from the results or developments expressed in, or implied by, these forward-looking statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following: product demand and market acceptance; competition in the Company’s markets and the risk of new competitors and new competitive product introductions; the Company’s reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company’s production capacity, efficiency and supply constraints; and other risks detailed in the Company’s press releases, shareholder communications and Securities and Exchange Commission filings, including the Company’s Form 10-K for the fiscal year ended September 30, 2011. Actual events affecting the Company and the impact of such events on the Company’s operations may vary from those currently anticipated.
Company’s e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com.
SOURCE The Female Health Company